SCHEMBL29370305

SCHEMBL29370305

Cc1cc(NC(=O)c2ccc(NS(=O)(=O)CCO)cc2N2CCC3(CC2)CC3)nc(N2CCO[C@@H](C)C2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KIF18A Q8NI77 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119492 1.00 KIF18A (1.00) KIF18A
SCHEMBL22148414 1.00 KIF18A (1.00) KIF18A
SCHEMBL22148403 0.96 KIF18A (1.00) KIF18A
SCHEMBL29370355 0.96 KIF18A (1.00) KIF18A
SCHEMBL22148406 0.94 KIF18A (1.00) KIF18A
SCHEMBL29371194 0.94 KIF18A (1.00) KIF18A
SCHEMBL29367909 0.92 KIF18A (1.00) KIF18A
SCHEMBL22148398 0.92 KIF18A (1.00) KIF18A
SCHEMBL22262199 0.91 KIF18A (1.00) KIF18A
SCHEMBL29370316 0.91 KIF18A (1.00) KIF18A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098029-A1 KIF18A INHIBITORS AMGEN INC. (US) 2026-04-09 — — US disclosed
US-12509442-B2 KIF18A inhibitors AMGEN INC. (US) 2025-12-30 — — US disclosed
US-20240317715-A1 KIF18A INHIBITORS AMGEN INC. (US) 2024-09-26 — — US disclosed
US-12054476-B2 KIF18A inhibitors AMGEN INC. (US) 2024-08-06 — — US disclosed
US-20220106293-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-04-07 — — US disclosed
US-11236069-B2 KIF18A inhibitors AMGEN INC. (US) 2022-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509442-B2 KIF18A inhibitors KIF18A, KIF18B, KIFC1 KIF18A 1/4885
US-20240317715-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 KIF18A 1/4885
US-20220106293-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 KIF18A 1/4885
US-12054476-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 KIF18A 1/4885
US-20260098029-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIFC1 KIF18A 1/4885
US-11236069-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 KIF18A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback